Ralect0.5 mg

Ralect is a selective irreversible inhibitor of monoamine oxidase type B (MAO-B), approved for the treatment of idiopathic Parkinson's disease (PD).

Established/FDA-Approved Uses

• Monotherapy in early idiopathic Parkinson's disease, to improve motor symptoms without the need for other antiparkinsonian agents.
• Adjunct therapy with levodopa (with or without other antiparkinsonian drugs) in patients with more advanced Parkinson's disease, including those experiencing "wearing-off" motor fluctuations.

Not Established / Off-Label

Ralect has been studied for possible disease-modifying (neuroprotective) effects in Parkinson's disease, but this benefit has not been definitively established, and it is not an approved indication.

Each tablet contains Rasagiline (as rasagiline mesylate) 0.5 mg or 1 mg as the active ingredient, along with pharmaceutically acceptable excipients such as mannitol, colloidal silicon dioxide, magnesium stearate, and starch.

Ralect is a propargylamine derivative that acts as a potent, selective, and irreversible inhibitor of the monoamine oxidase type B (MAO-B) enzyme. By reducing the breakdown of dopamine in the brain, it helps improve motor function in patients with Parkinson's disease. It is administered orally as tablets and is used either alone in early disease or in combination with levodopa in more advanced stages.

Ralect belongs to the class of anti-Parkinson's agents, specifically the selective monoamine oxidase type B (MAO-B) inhibitors.

Rasagiline irreversibly and selectively inhibits MAO-B, the enzyme primarily responsible for the metabolic breakdown of dopamine in the brain. By blocking this enzyme, Rasagiline increases extracellular dopamine levels in the striatum, which helps compensate for the dopamine deficiency characteristic of Parkinson's disease and improves motor symptoms.

Pharmacokinetics: Rasagiline is rapidly absorbed after oral administration, with peak plasma concentrations reached within about 1 hour; absolute bioavailability is approximately 36%. It is extensively metabolized in the liver, primarily via the CYP1A2 enzyme, to inactive metabolites, and is excreted mainly in urine. Recovery of MAO-B activity after stopping treatment takes about 1-2 weeks, consistent with irreversible enzyme inhibition.

Take Ralect tablets orally, once daily, at approximately the same time each day, with or without food. Swallow the tablet whole; do not crush or chew unless otherwise advised by a physician.

Ralect has several clinically significant drug interactions related to its MAO-B inhibitory activity:

• MAO inhibitors, meperidine, tramadol, methadone, propoxyphene, cyclobenzaprine, St. John's Wort, and other MAO-B inhibitors: Contraindicated in combination with Ralect due to the risk of serotonin syndrome and hypertensive crisis (see Contraindications).
• Antidepressants (SSRIs, SNRIs, tricyclic antidepressants): Concomitant use with Ralect is generally not recommended due to reported cases of serotonin syndrome (agitation, hyperthermia, myoclonus, autonomic instability); if combined, close monitoring is required, and an adequate washout period should be observed when switching between agents (e.g., at least 5 weeks after stopping fluoxetine before starting Ralect).
• CYP1A2 inhibitors (e.g., ciprofloxacin): May increase plasma levels of Ralect; dose reduction of Ralect is recommended.
• Dextromethorphan and sympathomimetics (e.g., in cold/allergy products, nasal/oral decongestants, some anesthetics): May increase the risk of adverse cardiovascular effects or psychosis-like reactions; avoid concomitant use.
• Tyramine-rich foods: At the recommended doses, dietary tyramine restriction is generally not required, but excessive intake of tyramine-rich foods (e.g., aged cheese, cured meats) should still be avoided as a precaution against hypertensive reactions.

Common Side Effects

• Headache
• Arthralgia (joint pain)
• Dyspepsia
• Flu-like symptoms
• Dizziness
• Depression

Dopaminergic/Monotherapy-Related Effects

• Orthostatic (postural) hypotension
• Dyskinesia and worsening of Parkinson's symptoms (with adjunct use)
• Nausea and vomiting
• Weight loss

Less Common but Important

• Impulse control disorders (e.g., pathological gambling, hypersexuality, compulsive shopping or eating) associated with dopaminergic therapy
• Sudden onset of sleep during daily activities, including driving
• Hallucinations and psychotic-like behavior
• Melanoma (patients with Parkinson's disease have a higher background risk; periodic skin monitoring is advised)

Patients should promptly report any unusual behavioral changes, fainting spells, or skin lesions to their physician.

Pregnancy: There are no adequate and well-controlled studies of Ralect in pregnant women. Animal studies have shown adverse developmental effects at doses relevant to human exposure. Ralect should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Lactation: It is not known whether Ralect is excreted in human breast milk. Because many drugs are excreted in breast milk and the effects on a nursing infant are unknown, a decision should be made whether to discontinue breastfeeding or discontinue the drug, taking into account the importance of treatment to the mother; consult a physician.

Use Ralect with caution and under close medical supervision in the following situations:

• Hypertensive crisis: Rare but serious hypertensive reactions can occur, particularly with concomitant use of sympathomimetics, other MAOIs, or excessive dietary tyramine (see Interactions and Contraindications). Monitor blood pressure and seek urgent care for symptoms such as severe headache, palpitations, or vision changes.
• Serotonin syndrome: Risk increases with concomitant serotonergic drugs such as antidepressants and certain opioids (see Interactions/Contraindications).
• Sudden sleep onset: Patients may fall asleep suddenly during activities of daily living, including driving; caution patients about operating machinery or driving until they know how Ralect affects them.
• Orthostatic hypotension: May increase the risk of falls, particularly when initiating therapy or increasing the dose; advise patients to rise slowly from sitting or lying positions.
• Impulse control disorders: Monitor for new or worsening compulsive behaviors (gambling, hypersexuality, binge eating, compulsive spending); dose reduction or discontinuation may be needed.
• Hepatic impairment: Requires dose adjustment in mild impairment and is not recommended in moderate to severe impairment.
• Skin lesions/melanoma: Periodic skin examinations are advised given the increased background risk of melanoma in Parkinson's disease patients.

Limited clinical experience with Ralect overdose is available. Reported and theoretically expected symptoms include severe hypotension or hypertension, dizziness, hallucinations, serotonin syndrome features (agitation, hyperthermia, muscle rigidity), and central nervous system depression or excitation. There is no specific antidote.

In case of a suspected overdose, seek immediate medical attention or contact a poison control center right away. Treatment is supportive and should be provided in a hospital setting with close monitoring of vital signs and cardiovascular status.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly

No overall differences in safety or effectiveness have been observed between elderly and younger patients, but as with any medication, use with appropriate monitoring given the higher likelihood of hepatic or renal impairment and concomitant medications in this population.

Hepatic Impairment

Dose adjustment required in mild impairment (maximum 0.5 mg daily); not recommended in moderate to severe hepatic impairment (see Contraindications).

Renal Impairment

No specific dose adjustment is established, but clinical data are limited; use with caution.

Pediatric Use

Safety and efficacy of Ralect in pediatric patients have not been established; it is not indicated for use in children.

Ralect is intended for long-term, typically indefinite use as part of the ongoing management of Parkinson's disease, since it does not cure the underlying condition but helps control symptoms. Duration of treatment should be determined and periodically reassessed by the treating physician based on individual response and tolerability. Discontinuation should be discussed with a physician, and an appropriate washout period observed before starting other interacting medications.

Anti-Parkinson's agent; Selective Monoamine Oxidase Type B (MAO-B) Inhibitor.

Rasagiline works by selectively and irreversibly inhibiting the enzyme monoamine oxidase type B (MAO-B) in the brain. This enzyme normally breaks down dopamine; by blocking it, Rasagiline increases the availability of dopamine in the brain, helping to reduce the motor symptoms of Parkinson's disease such as tremor, rigidity, and bradykinesia.

The safety and efficacy of Ralect in pediatric patients (below 18 years of age) have not been established. Ralect is not approved or recommended for use in children or adolescents, and its use in this population should be avoided outside of specific clinical circumstances directed by a specialist.